PF-Atlas › Clinical Trials › NCT04598919
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Saracatinab · Phase 1
Registry ID
NCT04598919
Phase
Phase 1
Status
Active, not recruiting
Drug / intervention
Saracatinab
Sponsor
National Jewish Health
Start
2020-11-12
About this trial
Saracatinab is evaluated in NCT04598919, a Phase 1 idiopathic pulmonary fibrosis study sponsored by National Jewish Health. Current status: Active, not recruiting.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT04598919 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.